EGFR ACTIVATING MUTATION
Clinical trials for EGFR ACTIVATING MUTATION explained in plain language.
Never miss a new study
Get alerted when new EGFR ACTIVATING MUTATION trials appear
Sign up with your email to follow new studies for EGFR ACTIVATING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New dosing strategy aims to fight lung Cancer's spread to the brain
Disease control Not yet recruitingThis study is testing if taking a higher dose of the lung cancer drug furmonertinib every other day is more effective and safe for patients whose cancer has spread to the lining of the brain and spinal cord. It will enroll 42 adults with a specific genetic mutation (EGFR) whose c…
Matched conditions: EGFR ACTIVATING MUTATION
Phase: NA • Sponsor: Guangzhou University of Traditional Chinese Medicine • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug combo aims to shrink tumors before lung cancer surgery
Disease control Not yet recruitingThis study is testing whether a high dose of the drug firmonertinib, combined with bevacizumab, can effectively shrink tumors before surgery in patients with a specific type of lung cancer (EGFR-mutated, non-small cell). The goal is to see if this pre-surgery treatment helps remo…
Matched conditions: EGFR ACTIVATING MUTATION
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
AI scans past to predict lung Cancer's future
Knowledge-focused Not yet recruitingThis study looks back at data from 1,000 past lung cancer patients to see if artificial intelligence (AI) can better predict outcomes. The AI analyzes patients' CT scans, tissue samples, and genetic test results to learn which patients are most likely to stay cancer-free after su…
Matched conditions: EGFR ACTIVATING MUTATION
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC